In an ancillary study of the PETACC-8 trial, KRAS mutations in exon 2 (codons 12 and 13) were examined in patients with stage III CRC receiving adjuvant chemotherapy [100]. The gene discussed is KRAS; the disease is colorectal carcinoma.